A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies

Trial Profile

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs BMS 986016 (Primary) ; Nivolumab (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 26 Apr 2017 Planned End Date changed from 1 Jan 2020 to 15 May 2020.
    • 26 Apr 2017 Planned primary completion date changed from 1 Feb 2018 to 28 Jun 2018.
    • 11 Jul 2016 Planned End Date changed from 1 Jun 2018 to 1 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top